Not Specific Cytokines but B Symptoms or C Reactive Proteins were Related the Infusion Reactions in Rituximab Treated B Cell Non-Hodgkin’s LymphomaYutaka Tsutsumi1*, Shinichi Ito1, Ryo Kikuchi1, Satomi Matsuoka1 and Takanori Teshima2
- *Corresponding Author:
- Tsutsumi Y
Department of Hematology
Hakodate Municipal Hospital 1-10-1
Minato-cho, Hakodate 041-8680, Japan
Tel: +81-138- 43-2000
E-mail: [email protected]
Received Date: May 28, 2017; Accepted Date: June 03, 2017; Published Date: June 10, 2017
Citation: Tsutsumi Y, Ito S, Kikuchi R, Matsuoka S, Teshima T (2017) Not Specific Cytokines but B Symptoms or C Reactive Proteins were Related the Infusion Reactions in Rituximab Treated B Cell Non-Hodgkin’s Lymphoma. J Blood Lymph 7: 164. doi: 10.4172/2165-7831.1000164
Copyright: © 2017 Tsutsumi Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Purpose: The purpose of this study is to analyze the risk factor for infusion related reaction (IRR) due to the rituximab treatment in patients with B cell non-Hodgkin’s lymphoma. Methods: A retrospective analysis was conducted the newly diagnosed B cell non-Hodgkin’s lymphoma patients who have received rituximab contained chemotherapy. Several factors with cytokines in patients were calculated. A P value <0.05 is significant. Results: 18 patients were included in the analysis. Most of patients were diffuse large B cell lymphoma or follicular lymphoma. Six patients had a IRR. TNF-α, IL6, IL8, sIL-2R, pre-administration of prednisolone were not observed significant differences. B symptom, CRP, gender was showed the significant differences in this analysis (B symptom: P=0.0139, gender: P=0.014, CRP: P=0.0354). Conclusion: B symptom, CRP, and gender might be important risk factors of the occurrence of IRR. Specific cytokines were not correlation with the IRR. Careful observation for IRR during rituximab administration is necessary for B cell non-Hodgkin’s lymphoma with B symptoms, and CRP positive patients.